Patents by Inventor Paul Richard Gellert

Paul Richard Gellert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION
    Publication number: 20240041834
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20240041835
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • Pharmaceutical composition
    Patent number: 11813246
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: November 14, 2023
    Assignees: AstraZeneca AB, Array BioPharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20220087982
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: May 6, 2021
    Publication date: March 24, 2022
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20200179344
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 9, 2019
    Publication date: June 11, 2020
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20190030004
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 31, 2019
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20170056375
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 2, 2017
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION 271
    Publication number: 20160030574
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • PHARMACEUTICAL COMPOSITION 271
    Publication number: 20120114750
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 10, 2012
    Applicants: ARRAY BIOPHARMA, INC, ASTRAZENECA AB
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • PHARMACEUTICAL COMPOSITION 271
    Publication number: 20090246274
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: March 26, 2009
    Publication date: October 1, 2009
    Applicants: AstraZeneca AB, Array Biopharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative
    Publication number: 20090186890
    Abstract: A pharmaceutical composition comprising 4-(3?-chloro-4?-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution.
    Type: Application
    Filed: September 19, 2008
    Publication date: July 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Paul Richard Gellert, Marcel De Matas, Michael Davis Parker
  • Formulation
    Publication number: 20080248077
    Abstract: The present invention relates to slow release anastrozole formulations, more particularly to biodegradable polymers, typically a polylactide or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer.
    Type: Application
    Filed: August 29, 2006
    Publication date: October 9, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Paul Richard Gellert, Balvinder Singh Matharu
  • Prolonged Release Formulations Comprising Anastrozole
    Publication number: 20080206303
    Abstract: The present invention relates to slow release anastrozole formulations, more particularly to in situ gelling formulations comprising a polylactide polymer or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer, and processes for the preparation of said formulations.
    Type: Application
    Filed: August 29, 2006
    Publication date: August 28, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Paul Richard Gellert, Balvinder Singh Matharu
  • Method for determining release of a peptide from a sustained release polylactide formulation
    Patent number: 7247491
    Abstract: A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate between batches of formulations for quality control purposes and to discriminate between formulations, for example, having different drug loadings.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: July 24, 2007
    Assignee: AstraZeneca AB
    Inventors: Brian Collingwood Clark, David Michael Cross, Paul Richard Gellert, Rodney Simon Kittlety
  • Formulation
    Publication number: 20040175402
    Abstract: The invention relates to a pharmaceutical formulation, preferably adapted for administration by injection, containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol and an antioxidant, more particularly to a formulation adapted for administration by injection containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentyl-sulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol in solution in a ricinoleate vehicle which comprises an antioxidant.
    Type: Application
    Filed: January 5, 2004
    Publication date: September 9, 2004
    Inventors: Paul Richard Gellert, Alison Margaret Potts
  • Method for determining release of a peptide from a sustained release polylactide formulation
    Publication number: 20040092452
    Abstract: A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate between batches of formulations for quality control purposes and to discriminate between formulations, for example, having different drug loadings.
    Type: Application
    Filed: April 8, 2003
    Publication date: May 13, 2004
    Inventors: Brian Collingwood Clark, David Michael Cross, Paul Richard Gellert, Rodney Simon Kittlety